Update shared on19 Aug 2025
Fair value Increased 6.62%Cochlear’s consensus price target has been revised upward, primarily reflecting improved revenue growth forecasts and a slight increase in net profit margin, resulting in a new fair value estimate of A$309.91.
What's in the News
- FDA approved Cochlear’s Nucleus Nexa System, the first smart cochlear implant system with upgradeable firmware, allowing recipients to access future innovations through both the implant and sound processor.
- Launched the Baha 7 Sound Processor with enhanced connectivity, a 55 dB HL fitting range, Bluetooth LE Audio, Auracast compatibility, and direct streaming from Apple and Android devices.
- Introduced the non-surgical Baha SoundBand with improved comfort and adjustability, expanding access for young children and supporting early auditory development.
- Updated Baha Smart App and Fitting Software with features to aid parents and clinicians in optimizing hearing outcomes for children.
Valuation Changes
Summary of Valuation Changes for Cochlear
- The Consensus Analyst Price Target has risen from A$290.68 to A$309.91.
- The Consensus Revenue Growth forecasts for Cochlear has risen from 10.3% per annum to 10.9% per annum.
- The Net Profit Margin for Cochlear has risen slightly from 18.04% to 18.43%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.